Navigation Links
ANI Pharmaceuticals Presents At Oppenheimer 24th Annual Healthcare Conference

BAUDETTE, Minn., Dec. 10, 2013 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) presented at the Oppenheimer & Co. 24th Annual Healthcare Conference at the Crowne Plaza Hotel in New York City.  On December 10, 2013 at 4:30pm, Arthur S. Przybyl, President and CEO, gave the presentation, which was webcast live at  The live webcast was archived and will be available through the prior link for 90 days through March 10, 2014.

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the potential benefits of the merger, the combined company's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of the combined company and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the combined company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include the risk that the Company may in the future be required to seek FDA approval for its unapproved products or withdraw such products from the market; the Company may fail to meet NASDAQ listing requirements; general business and economic conditions; the Company's need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of the Company's licensees or sublicensees. More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and this quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this release speak only as of the date made and are based on the Company's current beliefs and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information about ANI, please contact:
Arthur S. Przybyl
(218) 634-3608

SOURCE ANI Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
2. Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
3. Edison highlights the potential of GW Pharmaceuticals cannabinoid pipeline and furthers its US healthcare presence
4. Healthcare Companies Report Stock Price Updates, and Medical System Integration - Research Report on Johnson & Johnson, Geron, Ligand Pharmaceuticals, Masimo, and Capital Senior Living
5. Savara Pharmaceuticals Announces FDA Grant of Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Its Lead Product, AeroVanc
6. Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
7. Neuraltus Pharmaceuticals NP001 Phase 2 Results Highlighted at the 24th International Symposium on ALS/MND
8. Imprimis Pharmaceuticals Announces Plans to Pursue Compounding Pharmacy Strategy in Accordance with the Recently Passed Drug Quality and Security Act
9. Actinium Pharmaceuticals Announces Clinical Advisory Board Meeting At The 2013 ASH Conference
10. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
11. UPCOMING DEADLINE: Levi & Korsinsky, LLP Announces Class Action Against ARIAD Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 9, 2013 -- ARIA
Post Your Comments:
(Date:11/30/2015)... Medical Systems (NYSE: VAR ) has signed a Memorandum of ... the largest hospital chain in India , to ... country. The MoU was signed by Dr. K. Prabakar , ... Varian,s India managing director, in ... intends to deploy its Access to Care program by leveraging the ...
(Date:11/30/2015)... NAMUR , Belgium , Nov. 30, ... life sciences company focused on developing blood-based diagnostic tests for ... announced the Company will present at the LD Micro Conference, ... Los Angeles, CA. Attending from VolitionRx will ... and Scott Powell , Vice President of Investor Relations. ...
(Date:11/30/2015)... Mexico Healthcare and Life Sciences Report 2015 . --> ... Pharmaboardroom releases its new 98-page Mexico Healthcare and Life Sciences ... country of over 122 million people. --> Latin ... --> It offers companies, investors, policymakers, and stakeholders with an ... largest pharma and healthcare market in Latin America ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 2015 , ... The Foundation for Breast and Prostate Health ... forces with the award-winning creator and writer of Downton Abbey Julian Fellowes to ... the Union League of Philadelphia. , The benefit, titled “An Evening with ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a pioneer ... that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health ... awarded the largest Affordable Care Act grant for Federally Qualified Health Centers in ...
(Date:11/30/2015)... ... , ... In an interview with Andy Mitchell of Peconic Bay Medical Center, ... east end. During the broadcast, entitled “Eyes: the Window to the Soul,” Dr. Buono ... and how a visit with his grandmother to her physician put him on a ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... Kreithen”), one of the leading plastic surgery practices in Florida, is proud to ... to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson Company. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Vasont Systems, a top component ... (VUI) extension unites with Syncro Soft’s latest software update, oXygen XML editor Version ... with the latest release of oXygen® XML editor and the Vasont® CCMS. ...
Breaking Medicine News(10 mins):